{"id":170026,"date":"2025-08-11T06:30:52","date_gmt":"2025-08-11T10:30:52","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170026"},"modified":"2025-08-11T11:25:34","modified_gmt":"2025-08-11T15:25:34","slug":"eris-lifesciences-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/eris-lifesciences-q1-fy26-earnings-results\/","title":{"rendered":"ERIS Lifesciences Q1 FY26 Earnings Results"},"content":{"rendered":"<p>ERIS Lifesciences Limited is engaged in the manufacture and marketing of pharmaceutical products. Presenting below are its <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/febc630f-73fc-419d-8723-6abecc11fe56.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> Earnings Results.<\/p>\n<h2><strong>Q1 FY26 Earnings Results<\/strong><\/h2>\n<ul>\n<li>Revenue: \u20b9773 crore, up 7.36% year-on-year (YoY) from \u20b9720 crore in Q1 FY25.<\/li>\n<li>Total Expenses: \u20b9616 crore, up 1.65% YoY from \u20b9606 crore.<\/li>\n<li>Consolidated Net Profit (PAT): \u20b9125 crore, up 38.89% from \u20b990 crore in the same quarter last year.<\/li>\n<li>Earnings Per Share (EPS): \u20b98.66, up 41.50% from \u20b96.12 YoY.<\/li>\n<\/ul>\n<h2><strong>Operational &amp; Strategic Update<\/strong><\/h2>\n<ul>\n<li>Moderate Revenue Growth: The 7.36% increase in revenue reflects steady market demand and effective execution in product sales across key therapeutic segments.<\/li>\n<li>Controlled Expense Growth: Total expenses increased marginally by 1.65%, indicating strong cost discipline and operational efficiency gains.<\/li>\n<li><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/febc630f-73fc-419d-8723-6abecc11fe56.pdf\" target=\"_blank\" rel=\"noopener\">Significant Profitability Expansion<\/a>: Net profit and EPS surged nearly 39% and 42% respectively, indicating improved margins driven by cost control, better product mix, and operational leverage.<\/li>\n<li>Market &amp; Product Focus: ERIS Lifesciences continues to strengthen its position in the pharmaceutical market with a focus on specialty and chronic therapies, supported by a robust and diversified product portfolio.<\/li>\n<li>Strategic Initiatives: The company remains committed to innovation, expanding its therapeutic reach, and enhancing distribution networks to sustain growth and improve profitability.<\/li>\n<\/ul>\n<h2><strong>Corporate Developments in Q1 FY26 Earnings<\/strong><\/h2>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/febc630f-73fc-419d-8723-6abecc11fe56.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> results highlight ERIS Lifesciences Ltd\u2019s ability to deliver strong profit growth despite moderate revenue increase, underscoring effective cost management and favorable operational dynamics. The company\u2019s focus on high-value segments and geographic expansion has bolstered its financial performance.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-170027\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/EIRS.png\" alt=\"ERIS Q1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/EIRS.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/EIRS-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/EIRS-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/EIRS-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/EIRS-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<h2><strong>Looking Ahead<\/strong><\/h2>\n<p>ERIS Lifesciences Ltd is well-positioned to capitalize on growing demand in specialty pharmaceuticals and chronic care segments. Continued investments in R&amp;D, product innovation, and market expansion are expected to drive sustained revenue growth, margin enhancement, and shareholder value creation through FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/eris\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ERIS Lifesciences Limited is engaged in the manufacture and marketing of pharmaceutical products. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9773 crore, up 7.36% year-on-year (YoY) from \u20b9720 crore in Q1 FY25. Total Expenses: \u20b9616 crore, up 1.65% YoY from \u20b9606 crore. Consolidated Net Profit (PAT): \u20b9125 crore, up [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":170027,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-170026","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/EIRS.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172502,"url":"https:\/\/alphastreet.com\/india\/eris-lifesciences-q2-fy26-earnings-results\/","url_meta":{"origin":170026,"position":0},"title":"ERIS Lifesciences Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 19, 2025","format":false,"excerpt":"ERIS Lifesciences Ltd, engaged in the manufacturing and marketing of pharmaceutical products, reported robust financial results for Q2FY26. Financial Highlights: Revenues increased 6.88% year-on-year to \u20b9792 crore from \u20b9741 crore. Total expenses rose 1.14% to \u20b9623 crore from \u20b9616 crore. Consolidated net profit surged 39.58% to \u20b9134 crore from \u20b996\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/E-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/E-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/E-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/E-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/E-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/E-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170087,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-q1-fy26-earnings-results\/","url_meta":{"origin":170026,"position":1},"title":"Zydus Lifesciences Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 12, 2025","format":false,"excerpt":"In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Zydus Lifesciences Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170768,"url":"https:\/\/alphastreet.com\/india\/bajaj-hindustan-sugar-q1-fy26-earnings-results\/","url_meta":{"origin":170026,"position":2},"title":"Bajaj Hindustan Sugar Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 29, 2025","format":false,"excerpt":"Bajaj Hindusthan Sugar Ltd, incorporated in 1931, is engaged in manufacturing sugar, alcohol, ethanol, and power generation. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,248 crore, down 9.96% year-on-year (YoY) from \u20b91,386 crore in Q1 FY25. Total Expenses: \u20b91,335 crore, down 7.36% YoY from \u20b91,441\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"BAJAJHIND Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BAJAJHND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BAJAJHND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BAJAJHND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BAJAJHND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BAJAJHND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BAJAJHND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170588,"url":"https:\/\/alphastreet.com\/india\/alok-industries-q1-fy26-earnings-results\/","url_meta":{"origin":170026,"position":3},"title":"Alok Industries Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alok Industries Ltd is a textile company active in the cotton and polyester segments, involved in manufacturing textiles as well as leather and other apparel products. Presenting below are its Q1 FY26 Earnings Results Q1 FY26 Earnings Results Revenue: \u20b9932 crore, down 7.36% year-on-year (YoY) from \u20b91,006 crore in Q1\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALOKINDS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALOIND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALOIND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALOIND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALOIND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALOIND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALOIND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170582,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":170026,"position":4},"title":"Alkem Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25. Total Expenses: \u20b92,750 crore, up 8.61%\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALKEM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":170026,"position":5},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170026"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170026\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170027"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}